Company Details

Filters

Country

Sector & Industry

Market Cap

Enterprise Value

Ratings

Filters

Quant Rating

SA Author Rating

Wall St. Analysts Ratings

Quant Factor Grades

Filters

Valuation

Growth

Profitability

Momentum

EPS Revisions

Trading

Filters

Last Close Price

Yesterday's % Change

Dividend Grades

Filters

Dividend Safety

Dividend Growth

Dividend Yield

Dividend Consistency

Dividend

Earnings

Filters

Earnings Announce Date Range

EPS Surprise

Revenue Surprise

Valuation

Filters

P/E GAAP (TTM)

P/E Non-GAAP (FWD)

PEG GAAP (TTM)

PEG Non-GAAP (FWD)

Price / Sales (TTM)

EV / Sales (TTM)

EV / EBITDA (TTM)

Price / Book (TTM)

Price / Cash Flow (TTM)

Growth

Performance

Momentum

Filters

Last Price vs. 10D SMA

Last Price vs. 50D SMA

Last Price vs. 100D SMA

Last Price vs. 200D SMA

Weekly Volume/Shares

Profitability

Risk

Filters

Short Interest (% of Float)

Shares Short

Days to Cover

24M Beta

60M Beta

Altman Z Score

Ownership

Filters

Shares Outstanding

Float % Ownership

Insider Shares

Insider %

Institutional Shares

Institutional %

Amryt presents data for mycapssa® (oral octreotide) from optimal and mpowered phase 3 trials at endo 2022

Sign Up For Newsletters

Fidelitey

Fidelitey

Fidelitey

Fidelitey

Fidelitey

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt